

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/539,891	06/17/2005	Johnathan A Napier	13478-00001-US 7537		
23416 7590 03/07/2007 CONNOLLY BOVE LODGE & HUTZ, LLP			INER		
P O BOX 2207	EYAMNED	IG, LI			
WILMINGTON, DE 19899			ART UNIT	PAPER NUMBER	
			1638		
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE		
31 D	AYS	03/07/2007	PAP	PER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		Application No.	Applicant(s)		
		10/539,891	NAPIER ET AL.	NAPIER ET AL.	
Office Action Summary		Examiner	Art Unit		
		Li Zheng	1638		
		nication appears on the cover sheet w	ith the correspondence address		
	or Reply			_	
WHIC - Exte after - If NO - Failu Any	CHEVER IS LONGER, FROM THE N nsions of time may be available under the provision SIX (6) MONTHS from the mailing date of this com to period for reply is specified above, the maximum some to reply within the set or extended period for reply the set of th	FOR REPLY IS SET TO EXPIRE <u>1</u> NAILING DATE OF THIS COMMUN s of 37 CFR 1.136(a). In no event, however, may a munication. statutory period will apply and will expire SIX (6) MO y will, by statute, cause the application to become A after the mailing date of this communication, even i	CATION. reply be timely filed NTHS from the mailing date of this communicati BANDONED (35 U.S.C. § 133).		
atus					
1)🛛	Responsive to communication(s) fil	ed on 03 January 2007			
2a)□	This action is FINAL .	2b)⊠ This action is non-final.			
3)		for allowance except for formal ma	ters prosecution as to the merits	is	
~/		tice under Ex parte Quayle, 1935 C.I			
	·		., .,		
posit	ion of Claims				
4)🛛	Claim(s) $\underline{\text{1-25}}$ is/are pending in the	application.			
	4a) Of the above claim(s) <u>10-25</u> is/a	are withdrawn from consideration.			
5)	Claim(s) is/are allowed.				
6)[Claim(s) is/are rejected.				
7)	Claim(s) is/are objected to.				
8)🖂	Claim(s) <u>1-9</u> are subject to restriction	on and/or election requirement.			
plicat	ion Papers				
9)	The specification is objected to by the	he Examiner.			
,	•	e: a)□ accepted or b)□ objected to	by the Examiner.		
سار ۵۰	<u> </u>	ection to the drawing(s) be held in abeya			
		g the correction is required if the drawing		1(d).	
11)		to by the Examiner. Note the attache			
-		,	•		
•	under 35 U.S.C. § 119		0.440(-) (-1) (-1)		
	•	n for foreign priority under 35 U.S.C.	9 119(a)-(a) or (t).		
a)	☐ All b)☐ Some * c)☐ None of:	and a successful to the second			
	1. Certified copies of the priority		Annlination N.		
		y documents have been received in			
	<u> </u>	s of the priority documents have bee	n received in this National Stage		
	• •	onal Bureau (PCT Rule 17.2(a)).	t received		
7 3	see the attached detailed Office acti	on for a list of the certified copies no	received.		
	<i>"</i>				
Schmer	ut(s) ce of References Cited (PTO-892)	4) Interview	Summary (PTO-413)		
	ce of References Cited (P10-692) ce of Draftsperson's Patent Drawing Review ((PTO-948) Paper No	(s)/Mail Date		
	mation Disclosure Statement(s) (PTO/SB/08)		Informal Patent Application		

Application/Control Number: 10/539,891

Art Unit: 1638

DETAILED ACTION

The case has been transferred to Art Unit 1638, Examiner Li Zheng.

Applicants' election with traverse of group II, claim 1-9, and SEQ ID NO: 1, 3 and 5 in the reply filed on 1/03/2007 is acknowledged. The Applicants argue that even though the genes expressed in the transgenic organisms are different, they are integral parts of the present application and their shared technical feature, considered as a whole, contributes to the novelty of the claimed method. However, Applicants are reminded that different nucleotide sequences and amino acid sequences are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute different inventive concepts.

In addition, further species election is also required for the elected group, Group II, as following:

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

1) Species listed for R1 in claim 1; 2) Species listed for R2 in claim 1 (if applicable); 3) Species listed for R3 in claim 1 (if applicable); 4) numbers listed for n in claim 1; 5) numbers listed for m in claim 1; 6) numbers listed for p in claim 1; 7) plant species listed in claim 7;

Application/Control Number: 10/539,891

Art Unit: 1638

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The following claim(s) are generic: claim 1.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: The species are different compounds and the do not share a same technical feature.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

Art Unit: 1638

remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Li Zheng whose telephone number is 571-272-8031. The examiner can normally be reached on Monday through Friday 9:00 AM - 5:30 PM EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg can be reached on 571-272-0975. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ELIZABETH MCELMAIN PRIMARY EXAMINER Application/Control Number: 10/539,891

Art Unit: 1638

Page 5